License #80109555 was granted in April for ParActin 50% total andrographolides (comprised of andrographolide, 14-deoxyandrographolide, neoandrographolide): specifically, that 1 capsule 150 mg twice daily “Helps to relieve joint health associated with osteoarthritis of the knee.”
Annie Eng, CEO, HP Ingredients, welcomed the announcement, saying: “Canadian consumers will now be able to purchase ParActin-containing supplements clearly for joint health, and can be comfortable discussing usage with their osteopaths, general practitioners and naturopaths.”
“This license reinforces the 40 years plus clinical research experience of Dr. Juan Hancke of the Universidad Austral de Chile, and Chief Scientific Officer of HP Ingredients,” she added.
The ingredient is supported by two human clinical trials. The first was published in 2009 in Clinical Rheumatology (Burgos, et al. Vol. 28, pp. 931–946) and included 60 people with active rheumatoid arthritis.
A 2019 paper in Phytotherapy Research (Hancke et al, Vol. 33, No. 5, pp. 1469-1479) included 103 adults with osteoarthritis. Daily ParActin doses of 300 or 600 mg were associated with significant reductions in knee pain, and improvements in measured of stiffness, physical function, and fatigue, compared with the placebo group.
“Health Canada is sometimes looked at as the ‘gold standard’ when reviewing claims, because two double-blind placebo-controlled, peer-reviewed published human studies are required to make the claim,” added Eng. “Health Canada licensure also provides our US customers that are marketing ParActin in the US (and around the world) the confidence when making DSHEA-compliant structure function claims.”
